Petros Family Wealth LLC Invests $271,000 in Gilead Sciences, Inc. (NASDAQ:GILD)

Petros Family Wealth LLC bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, HoldingsChannel reports. The firm bought 2,931 shares of the biopharmaceutical company’s stock, valued at approximately $271,000.

Other institutional investors have also bought and sold shares of the company. XTX Topco Ltd acquired a new position in Gilead Sciences in the third quarter valued at approximately $581,000. Westside Investment Management Inc. increased its stake in shares of Gilead Sciences by 3.5% in the 3rd quarter. Westside Investment Management Inc. now owns 27,443 shares of the biopharmaceutical company’s stock valued at $2,249,000 after acquiring an additional 917 shares in the last quarter. SkyView Investment Advisors LLC lifted its position in shares of Gilead Sciences by 5.4% during the 3rd quarter. SkyView Investment Advisors LLC now owns 8,482 shares of the biopharmaceutical company’s stock valued at $711,000 after acquiring an additional 435 shares during the period. Pine Valley Investments Ltd Liability Co bought a new position in Gilead Sciences during the third quarter worth $209,000. Finally, Sanctuary Advisors LLC grew its holdings in Gilead Sciences by 28.8% in the third quarter. Sanctuary Advisors LLC now owns 183,289 shares of the biopharmaceutical company’s stock worth $16,531,000 after purchasing an additional 40,951 shares during the period. Institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on GILD. Morgan Stanley upped their price objective on shares of Gilead Sciences from $123.00 to $130.00 and gave the company an “overweight” rating in a report on Tuesday, March 11th. DZ Bank upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price target on the stock in a report on Thursday, February 13th. Royal Bank of Canada raised their price objective on Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a research note on Wednesday, February 12th. The Goldman Sachs Group upped their target price on Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 12th. Finally, Bank of America lifted their price target on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a “buy” rating in a research report on Wednesday, March 5th. Eleven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $105.12.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 17,929 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the sale, the chief financial officer now directly owns 169,061 shares in the company, valued at approximately $19,977,938.37. This represents a 9.59 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders sold 302,785 shares of company stock valued at $30,503,250 over the last ninety days. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Trading Up 2.2 %

NASDAQ GILD opened at $103.63 on Friday. The business’s fifty day moving average is $108.34 and its 200-day moving average is $96.79. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The stock has a market capitalization of $129.04 billion, a price-to-earnings ratio of 280.08, a PEG ratio of 0.71 and a beta of 0.32. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Equities research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Friday, March 14th were issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 3.05%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend was Friday, March 14th. Gilead Sciences’s dividend payout ratio is 854.05%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.